Unknown

Dataset Information

0

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.


ABSTRACT: Background: Acute myeloid leukemia (AML) is a heterogeneous disease that frequently relapses after standard chemotherapy. Therefore, there is a need for the development of novel chemotherapeutic agents that could treat AML effectively. Radotinib, an oral BCR-ABL tyrosine kinase inhibitor, was developed as a drug for the treatment of chronic myeloid leukemia. Previously, we reported that radotinib exerts increased cytotoxic effects towards AML cells. However, little is known about the effects of combining radotinib with Ara-C, a conventional chemotherapeutic agent for AML, with respect to cell death in AML cells. Therefore, we investigated combination effects of radotinib and Ara-C on AML in this study.

Methods: Synergistic anti-cancer effects of radotinib and Ara-C in AML cells including HL60, HEL92.1.7, THP-1 and bone marrow cells from AML patients have been examined. Diverse cell biological assays such as cell viability assay, Annexin V-positive cells, caspase-3 activity, cell cycle distribution, and related signaling pathway have been performed.

Results: The combination of radotinib and Ara-C was found to induce AML cell apoptosis, which involved the mitochondrial pathway. In brief, combined radotinib and Ara-C significantly induced Annexin V-positive cells, cytosolic cytochrome C, and the pro-apoptotic protein Bax in AML cells including HL60, HEL92.1.7, and THP-1. In addition, mitochondrial membrane potential and Bcl-xl protein were markedly decreased by radotinib and Ara-C. Moreover, this combination induced caspase-3 activity. Cleaved caspase-3, 7, and 9 levels were also increased by combined radotinib and Ara-C. Additionally, radotinib and Ara-C co-treatment induced G0/G1 arrest via the induction of CDKIs such as p21 and p27 and the inhibition of CDK2 and cyclin E. Thus, radotinib/Ara-C induces mitochondrial-dependent apoptosis and G0/G1 arrest via the regulation of the CDKI-CDK-cyclin cascade in AML cells. In addition, our results showed that combined treatment with radotinib and Ara-C inhibits AML cell growth, including tumor volumes and weights in vivo. Also, the combination of radotinib and Ara-C can sensitize cells to chemotherapeutic agents such as daunorubicin or idarubicin in AML cells.

Conclusions: Therefore, our results can be concluded that radotinib in combination with Ara-C possesses a strong anti-AML activity.

SUBMITTER: Heo SK 

PROVIDER: S-EPMC7718665 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.

Heo Sook-Kyoung SK   Noh Eui-Kyu EK   Yu Ho-Min HM   Kim Do Kyoung DK   Seo Hye Jin HJ   Lee Yoo Jin YJ   Cheon Jaekyung J   Koh Su Jin SJ   Min Young Joo YJ   Choi Yunsuk Y   Jo Jae-Cheol JC  

BMC cancer 20201204 1


<h4>Background</h4>Acute myeloid leukemia (AML) is a heterogeneous disease that frequently relapses after standard chemotherapy. Therefore, there is a need for the development of novel chemotherapeutic agents that could treat AML effectively. Radotinib, an oral BCR-ABL tyrosine kinase inhibitor, was developed as a drug for the treatment of chronic myeloid leukemia. Previously, we reported that radotinib exerts increased cytotoxic effects towards AML cells. However, little is known about the effe  ...[more]

Similar Datasets

| S-EPMC5681687 | biostudies-other
| S-EPMC3040224 | biostudies-literature
| S-EPMC5526043 | biostudies-other
| S-EPMC7980395 | biostudies-literature
| S-EPMC10796764 | biostudies-literature
| S-EPMC6219441 | biostudies-literature
| S-EPMC9140039 | biostudies-literature
| S-EPMC10637411 | biostudies-literature
| S-EPMC5085189 | biostudies-literature
| S-EPMC3066101 | biostudies-literature